Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer - PubMed
5 hours ago
- #PARP Inhibitor
- #Prostate Cancer
- #Immunotherapy
- Phase II study of olaparib and durvalumab in metastatic castration-resistant prostate cancer (mCRPC).
- Combination therapy aimed to expand benefits beyond HRR-altered disease.
- Median radiographic progression-free survival (rPFS) was 5.0 months, and median overall survival (OS) was 19.1 months.
- Patients with BRCA2 variants had longer rPFS (13.2 months) compared to those without (4.8 months).
- Higher baseline ctDNA fraction correlated with radiographic progression and shorter time-to-progression.
- Treatment induced early peripheral immune changes, including inflammatory cytokine increases and T cell expansion.
- Lower IL1R2 expression in PBMC was associated with longer OS.
- Modest activity observed in HRR-unselected mCRPC, with enhanced benefit in BRCA2-variant cases.